Teva Active Pharmaceutical Ingredients

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Retrieved on: 
Tuesday, November 7, 2023

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).

Key Points: 
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api).
  • Richard Francis, Teva’s President and CEO said: “I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business.
  • Having led the former Teva api and Biologics Operations organization at Teva from 2014 to 2018, Dr. Ananth has a deep understanding of Teva’s API business.
  • Dr. Ananth stated, “I am very excited to return to Teva to lead the API business, and to join my esteemed colleagues and teams at Teva api – old and new.

Medical Spa Expert DermaGym Joins Exclusive Haute Beauty Network

Retrieved on: 
Tuesday, October 31, 2023

NEW YORK, Oct. 31, 2023 /PRNewswire-PRWeb/ -- With over two decades of professional experience, Liz Lam is an expert in the pharmaceutical industry. Specializing in business administration, she founded DermaGym LLC, an anti-aging spa in Miami, in 2016. As the founder of the business, she is responsible for growing the brand and developing further business opportunities. Ms. Lam and the business have worked with several luxury hotels in Miami Beach, including Nobu Hotel and Eden Roc, where they served as its resident medical spa in 2020, hosting monthly Botox and bubble events. Likewise, they were featured in the Trump International Beach Resort's guest brochure. Ms. Lam has also served as the president of LLC Federal Solutions since 2009. She previously operated as a regional account manager for Bioanalytical Systems, Inc., between 2009 and 2010. She originally began her career in 2000, working as an account manager for MBNA Corporation until 2001.

Key Points: 
  • DermaGym joins Haute Beauty Network as a medical spa expert representing the Miami, FL market.
  • NEW YORK, Oct. 31, 2023 /PRNewswire-PRWeb/ -- With over two decades of professional experience, Liz Lam is an expert in the pharmaceutical industry.
  • Specializing in business administration, she founded DermaGym LLC, an anti-aging spa in Miami, in 2016.
  • DermaGym LLC's new collaborations will include upscale luxury residential buildings in Edgewater, Sunny Isles, and surrounding Miami neighborhoods.

Joseph Jimenez, Global Quality Leader, Joins Validant Group

Retrieved on: 
Thursday, October 5, 2023

The Validant Group, a leading global provider of comprehensive and innovative regulatory consulting services for the life sciences industry, today announced that Joseph Jimenez has joined the firm as Partner.

Key Points: 
  • The Validant Group, a leading global provider of comprehensive and innovative regulatory consulting services for the life sciences industry, today announced that Joseph Jimenez has joined the firm as Partner.
  • Joseph is a global quality leader with a career spanning nearly 30-years in the pharmaceutical, medical device, human tissue, and consumer goods organizations.
  • His experience enhances the Validant Group’s quality assurance and strategic regulatory compliance capabilities.
  • The Validant Group is a global, full-service life science consulting company focused on managing and resolving complex regulatory issues.

U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

Retrieved on: 
Tuesday, October 3, 2023

Mr. Singh addressed his appointment on Monday with enthusiasm, stating, “I think Bright Green is positioned with an opportunity to not only be the premier cultivator, manufacturer, and supplier of a new, groundbreaking class of Active Pharmaceuticals Ingredients, but also to form a trusted network of domestic and international partners that can facilitate the expansion of this impactful approach to medicine and therapies. This is the vision that is shared across the Founders and Board Members of Bright Green -- to have everything under one roof and “Made in the USA” from start to finish.” Singh continued, “I am eager to leverage the monumental achievements that Bright Green’s leadership has already solidified, including the EB-5 program and our existing international exposure—an element I am particularly looking forward to building on.”

Key Points: 
  • GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer.
  • Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently developed health-related concerns.
  • McAuley will assume an advisory role to Mr. Singh during the transition to continue facilitating the company’s success while remaining focused on his recovery.
  • We offer him nothing but our support moving forward,” Terry Rafih, Executive Chairman of the Board of Directors for Bright Green said Monday.

Revolutionizing Pharmaceutical Supply Chains: SpendEdge's API Supplier Optimization

Retrieved on: 
Wednesday, September 27, 2023

Our client, a prominent German-based pharmaceutical company renowned for its range of vital medications, faced persistent challenges with API (Active Pharmaceutical Ingredient) deliveries and regulatory compliance from several suppliers.

Key Points: 
  • Our client, a prominent German-based pharmaceutical company renowned for its range of vital medications, faced persistent challenges with API (Active Pharmaceutical Ingredient) deliveries and regulatory compliance from several suppliers.
  • Client Overview: Our client, a leading pharmaceutical company, grappled with delayed API deliveries and regulatory non-compliance among some API suppliers.
  • Our API Supplier Optimization Solution delivered remarkable results:
    Mitigated Delivery Delays: By onboarding reliable API suppliers, we successfully mitigated the challenges related to delayed deliveries, ensuring consistent production schedules.
  • In conclusion, SpendEdge's API Supplier Optimization Solution revolutionized our client's pharmaceutical supply chain.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Friday, September 8, 2023

LONDON, Sept. 8, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.

Global Active Pharmaceutical Ingredients Market Outlook & Forecast 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023

The "Active Pharmaceutical Ingredients (APIs) Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Active Pharmaceutical Ingredients (APIs) Market - Global Outlook & Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global active pharmaceutical ingredients (API) market is expected to grow at a CAGR of 6.67% from 2022 to 2028.
  • Digital Transformation has allowed the active pharmaceutical ingredients (API) market to reshape itself to optimize production, streamline processes and reduce costs.
  • The active pharmaceutical ingredients (API) market is concentrated, competitive, and characterized by numerous global and domestic vendors across geographies.

RK Pharma to receive up to USD 200 million investment from PAG

Retrieved on: 
Tuesday, June 6, 2023

RK Pharma Inc, a vertically integrated pharmaceutical company based in the U.S. with subsidiaries in India, announced today an investment of up to 200 million USD from PAG, a leading global investment firm.

Key Points: 
  • RK Pharma Inc, a vertically integrated pharmaceutical company based in the U.S. with subsidiaries in India, announced today an investment of up to 200 million USD from PAG, a leading global investment firm.
  • RK Pharma group of companies include subsidiaries Apicore, Archis Pharma and Aktinos Pharma.
  • Dr. Ravishanker Kovi, founder & Executive Chairman of RK Pharma and his executive management team will be partnering with PAG.
  • I would like to sincerely thank RK Pharma for the opportunity to advise on the transaction.”
    Sheppard, Mullin, Richter and Hampton LLP acted as legal counsel to RK Pharma Inc. on the deal.